These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22152723)

  • 1. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
    Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
    Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of canakinumab in the cryopyrin-associated periodic syndrome.
    Lachmann HJ; Kone-Paut I; Kuemmerle-Deschner JB; Leslie KS; Hachulla E; Quartier P; Gitton X; Widmer A; Patel N; Hawkins PN;
    N Engl J Med; 2009 Jun; 360(23):2416-25. PubMed ID: 19494217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
    Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
    Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
    Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
    Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
    Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
    Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
    Curran MP
    BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
    Sibley CH; Chioato A; Felix S; Colin L; Chakraborty A; Plass N; Rodriguez-Smith J; Brewer C; King K; Zalewski C; Kim HJ; Bishop R; Abrams K; Stone D; Chapelle D; Kost B; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
    Ann Rheum Dis; 2015 Sep; 74(9):1714-9. PubMed ID: 24906637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.
    Brogan PA; Hofer M; Kuemmerle-Deschner JB; Koné-Paut I; Roesler J; Kallinich T; Horneff G; Calvo Penadés I; Sevilla-Perez B; Goffin L; Lauwerys BR; Lachmann HJ; Uziel Y; Wei X; Laxer RM
    Arthritis Rheumatol; 2019 Nov; 71(11):1955-1963. PubMed ID: 31161734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
    Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
    Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China.
    Zhu X; Fan J; Huang Y; Xu Y; Yang Z; Weng R; Luo Y; Yang J; He T
    Pediatr Rheumatol Online J; 2024 Sep; 22(1):87. PubMed ID: 39334417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.
    Yokota S; Imagawa T; Nishikomori R; Takada H; Abrams K; Lheritier K; Heike T; Hara T
    Clin Exp Rheumatol; 2017; 35 Suppl 108(6):19-26. PubMed ID: 27974104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.
    Schlesinger N; De Meulemeester M; Pikhlak A; Yücel AE; Richard D; Murphy V; Arulmani U; Sallstig P; So A
    Arthritis Res Ther; 2011 Mar; 13(2):R53. PubMed ID: 21439048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
    Feist E; Burmester GR
    Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
    Miyamoto T; Izawa K; Masui S; Yamazaki A; Yamasaki Y; Matsubayashi T; Shiraki M; Ohnishi H; Yasumura J; Kawabe T; Miyamae T; Matsubara T; Arakawa N; Ishige T; Takizawa T; Shimbo A; Shimizu M; Kimura N; Maeda Y; Maruyama Y; Shigemura T; Furuta J; Sato S; Tanaka H; Izumikawa M; Yamamura M; Hasegawa T; Kaneko H; Nakagishi Y; Nakano N; Iida Y; Nakamura T; Wakiguchi H; Hoshina T; Kawai T; Murakami K; Akizuki S; Morinobu A; Ohmura K; Eguchi K; Sonoda M; Ishimura M; Furuno K; Kashiwado M; Mori M; Kawahata K; Hayama K; Shimoyama K; Sasaki N; Ito T; Umebayashi H; Omori T; Nakamichi S; Dohmoto T; Hasegawa Y; Kawashima H; Watanabe S; Taguchi Y; Nakaseko H; Iwata N; Kohno H; Ando T; Ito Y; Kataoka Y; Saeki T; Kaneko U; Murase A; Hattori S; Nozawa T; Nishimura K; Nakano R; Watanabe M; Yashiro M; Nakamura T; Komai T; Kato K; Honda Y; Hiejima E; Yonezawa A; Bessho K; Okada S; Ohara O; Takita J; Yasumi T; Nishikomori R;
    Arthritis Rheumatol; 2024 Jun; 76(6):949-962. PubMed ID: 38268504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study.
    Mulders-Manders CM; Kanters TA; van Daele PLA; Hoppenreijs E; Legger GE; van Laar JAM; Simon A; Hakkaart-van Roijen L
    Orphanet J Rare Dis; 2018 Apr; 13(1):59. PubMed ID: 29678136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
    Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome.
    Elmi AA; Wynne K; Cheng IL; Eleftheriou D; Lachmann HJ; Hawkins PN; Brogan P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):36. PubMed ID: 31287007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.